| Autor: |
T.J. Monberg, T. Kudling, B. Albieri, S. Pakola, E. Ellebaek, M. Donia, R.L. Eefsen, C. von Buchwald, C. Kistler, J.M. Santos, J. Clubb, L. Haybout, M.C.W. Westergaard, D.C.A. Quixabeira, E. Jirovec, R. Havunen, S. Sorsa, V. Cervera-Carrascon, A. Hemminki, I.M. Svane |
| Jazyk: |
angličtina |
| Rok vydání: |
2024 |
| Předmět: |
|
| Zdroj: |
Immuno-Oncology and Technology, Vol 24, Iss , Pp 100726- (2024) |
| Druh dokumentu: |
article |
| ISSN: |
2590-0188 |
| DOI: |
10.1016/j.iotech.2024.100726 |
| Popis: |
Background: Despite significant advancements in the treatment of malignant melanoma, metastatic mucosal melanoma remains a therapeutic challenge due to its complex pathogenesis, distinct pathological characteristics, and limited response to immunotherapy. Combining different immunotherapeutic approaches offers a potential strategy to address these challenges. Tumor-infiltrating lymphocyte (TIL) therapy and oncolytic virus therapy represent promising treatment modalities that may synergize with each other. Patient and methods: We present a case of a 48-year-old woman with metastatic sinonasal mucosal melanoma who achieved a durable complete pathological response following treatment with multiple injections of the oncolytic virus TILT-123 (igrelimogene litadenorepvec) and a single infusion of TILs, without preconditioning chemotherapy or postconditioning interleukin-2. Results: Immunohistochemical analysis and single-cell sequencing revealed interesting alterations in injected and noninjected tumors as well as in peripheral blood, during the treatment course, suggesting that TILT-123 facilitated TIL engraftment into the tumor, ultimately leading to a complete response. Conclusions: This case underscores the potential of combined immunotherapeutic approaches as a promising strategy for patients with metastatic mucosal melanoma. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
